Search

everythinglearnresearchcommunity

for

Search:↓

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

The conversation discusses whether individuals using hair loss treatments like Dutasteride (Dut) or Finasteride (Fin) should regularly check their hormone levels through bloodwork. Some argue it's important to monitor the effects of these medications on hormone levels, while others believe it's unnecessary if there are no side effects, citing cost and practicality concerns.

A user discusses a company, Roots by Genetic Arts, that offers a genetic test for hair loss to create personalized treatments, and is curious about its legitimacy and the science behind it. The company tests 16 genes related to hair loss and compounds a topical treatment based on the results.

South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Hair loss may be caused by calcification of capillaries in the scalp, restricting blood flow to hair follicles. A daily treatment regimen including high doses of Vitamins D and K, Magnesium, and Nattokinase could potentially decalcify these capillaries, improving blood flow and hair growth. However, some users warn against excessive Vitamin D intake and emphasize the need for medical consultation.

Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Han Bio plans to start clinical trials for a new hair multiplication technology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.

A user diagnosed with Crohn's disease is concerned it might contribute to balding. They have been using keto shampoo, finasteride, and oral minoxidil, which improved their hair but not significantly.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.

The conversation is about the difference in hair loss between bodybuilders in the "Golden Era" and modern bodybuilders. Some users speculate that factors such as the types and doses of steroids used, genetics, diet, microplastics, and overall health may contribute to hair loss. Hair loss prevention medication and transplants are mentioned as potential treatments.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.

The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hair follicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hair loss.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

Hair loss is influenced by scalp tension, stress, and environmental factors, not just hormones. Treatments like tretinoin, microneedling, scalp massage, and Botox can reduce tension and improve hair health.